Our study specifically explored the efficacy of adjuvant TKI therapy in EGFRm patients and showed a trend towards improved DFS and DMFS with adjuvant TKI therapy compared to PORT or adjuvant chemotherapy alone.
← all excerpts
Postoperative radiotherapy improves disease-free survival of EGFR wild-type pN2 non-squamous-cell non-small-cell lung cancer (Nsq-NSCLC) patients after complete resection: a propensity score matching analysis.
1
—
—